Biotech Values

[DewDiligence]

EGRX +14% on Bendeka launch and “hard switch” from Treanda to Bendeka effective 3/30/16:

http://www.sec.gov/Archives/edgar/data/827871/000110465916091950/a16-3075_18k.htm

Eagle Pharmaceuticals, Inc. (Nasdaq: EGRX) is announcing that Teva Pharmaceuticals has commenced shipment of BENDEKA (bendamustine hydrochloride) injection, a liquid, low-volume (50 mL) and short-time 10-minute infusion formulation of bendamustine.

…According to Paul Rittman, Senior Vice President and General Manager, Teva Oncology, “With the launch of BENDEKA, Teva furthers our commitment to providing treatment options for patients with these rare forms of cancer. We believe BENDEKA represents an important benefit to both patients and healthcare providers, and are pleased it is now available. Based on the product profile, we expect BENDEKA to replace TREANDA liquid.”

The 3/30/16 date for TEVA’s discontinuation of Treanda liquid comes from TEVA’s internal documents (sorry, no link).